CTLA4 and cancer: In this case, anti-CTLA-4 and anti-TIGIT therapies not only led to a reduction in the percentage of mesenchymal EpCAM− cancer cells but also induced the enrichment of epithelial EpCAM+ cancer cells (Fig. 6q, r).